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Marieke C. H. Hogenes,1 Suzanne van Dorp,2 Joyce van Kuik,1
Filipa R. P. Monteiro,1 Natalie ter Hoeve,1 Marijke R. van Dijk,1
Anton C. Martens,3,4 Roel A. de Weger1Graft-versus-host disease (GVHD) remains a frequently occurring and difficult-to-treat complication in hu-
man allogeneic stem cell transplantation. Murine transplantation models are often used to study and under-
stand the complex pathogenesis of GVHD and to explore new treatment strategies. Although GVHD
kinetics may differ in murine and humanmodels, adequatemodels are essential for identification of the crucial
factors responsible for the major pathology in GVHD. We present a detailed description of the specific his-
tological features of a graft-versus-host–induced fibrotic response in xenogeneic RAG22/2gc2/2 mice after
total body irradiation and injection with human peripheral blood mononuclear cells. We describe the full
morphological features of this reaction, including a detailed analysis of the specific tissue infiltration patterns
of the human peripheral bloodmononuclear cells. Our data show the development of fibrosis, predominantly
near blood vessels, and reveal different cell populations and specific cell migration patterns in the affected
organs. The combination of immunohistochemical cell characterization and mRNA expression analysis of
both human (donor)- and murine (host)-derived cytokines reveals an interaction between host tissues
and donor-derived cells in an entangled cytokine profile, in which both donor- and host-derived cytokines
contribute to the formation of fibrosis.
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Graft-versus-host disease (GVHD) is a major
problem in allogeneic stem cell transplantation, caus-
ing late morbidity and mortality [1] and affecting
a wide range of organs [2]. One of the difficulties faced
in combating GVHD is a poor understanding of the
pathophysiology of the syndrome [3]. Steroid therapy
and calcineurin inhibitors are currently the most com-
mon pharmacologic agents used for treatment and/or
prevention of GVHD, although other cells, such as B
cells, dendritic cells, macrophages and regulatory T1Department of Pathology; 2Hematology; 3Cell Biology;
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6/j.bbmt.2012.05.002cells (Tregs), might be relevant therapeutic targets as
well [4-10].
The study of human GVHD development in vivo
has used several different experimental models based
on immunodeficient mouse strains, including severe
combined immunodeficient (SCID) mice, nonobese
diabetic severe immunodeficient (NOD-SCID)
mice, and the RAG22/2gc2/2 mice [11-15]. Several
xenogeneic mouse models have been reported [15-20],
but only a few of these are considered specific GVHD
models [15,21-23]. In these mice, human peripheral
blood mononuclear cells (huPBMCs), including
lymphocytes, are injected into the mice, and the
subsequent development of GVHD is studied. To
assess the development of the graft-versus-host (GVH)
reaction, most studies have focused on the clinical ap-
pearance and associated parameters of the mice. How-
ever, little is known of the histopathological origin that
forms the basis of these ‘‘clinical’’ aspects, and the histo-
logical patterns and topographic locations of the differ-
ent human and murine inflammatory cells has received
only minimal attention [15,21,23-25].
In this article, we present a detailed (immuno)his-
tochemical analysis of the localization of human1023
1024 Biol Blood Marrow Transplant 18:1023-1035, 2012M. C. H. Hogenes et al.immune cells in various organs, as well as the sites of
GVH-induced fibrosis in the RAG22/2gc2/2 mouse
model. In an attempt to identify the trigger of fibrosis,
we used quantitative PCR (qPCR) to measure the
mRNA expression of human and murine cytokines in
affected tissues. This allows us to examine whether
fibrosis is induced by human cytokines directly or by
murine cytokines in a reaction to the damage inflicted
by human cells.MATERIALS AND METHODS
Mice and Conditioning Regiments
RAG22/2gc2/2 and Balb/c mice were obtained
from the Netherlands Cancer Institute [26]. The
mice were bred andmaintained in filtertop cages under
specified pathogen-free conditions at the Central Ani-
mal Laboratory Institute of Utrecht University and
were given sterilized food pellets and sterile water ad
libitum. The experiment was performed twice.
In each experiment, 10 female mice aged 15-16
weeks received total body irradiation with a single
dose of 350 cGy (gamma irradiation from a linear ac-
celerator) and were injected i.v. with huPBMCs the
next day. Control groups of 5 RAG22/2gc2/2 mice
and 2 Balb/c mice were irradiated but did not receive
huPBMCs. Tissues from both control groups were
used, to test for specificity of human reagents.
Mice were weighed once a week and sacrificed by
cervical dislocation when a loss of .15% of original
body weight or severe GVH-associated morbidity
was noted. Survival varied between mice, ranging
from 29 to 70 days. Experiments were conducted after
permission was granted by the local Ethical Commit-
tee for Animal Experiments and in accordance with
the Dutch law on animal experimentation.
Preparation and Transplantation of huPBMCs
The huPBMCs were prepared as described by van
Rijn et al. [15]. In brief, fresh buffy coats were obtained
from healthy human volunteers at the blood bank
of the University Medical Centre Utrecht, andTable 1. Antibodies Used for Immunohistochemical Detection of H
Primary Antibody Manufacturer Animal Monoclonal or Pol
Hu-CD2 Novocastra Mouse Monoclonal
Hu-CD4 Monosan Xtra Mouse Monoclonal
Hu-CD8 DakoCytomation Mouse Monoclonal
Hu-CD20 DakoCytomation Mouse Monoclonal
Hu-CD79a DakoCytomation Mouse Monoclonal
Hu-CD138 Serotec Mouse Monoclonal
Hu-k DakoCytomation Rabbit Polyclonal
Hu-l DakoCytomation Rabbit Polyclonal
Hu-plasmacell DakoCytomation Mouse Monoclonal
Hu-CD68 Novocastra Mouse Monoclonal
Hu-FoxP3 EBioscience Rat Monoclonal
Mouse-CD68 Hycult Biotech Rat MonoclonalhuPBMCs were isolated using Fiqoll Hypaque (Phar-
macia, Uppsala, Sweden) density centrifugation. Cells
were washed twice in PBS and resuspended in PBS/
0.1% human serum albumin (HSA). Fresh cell suspen-
sions of 0.2 mL containing 15-30  106 huPBMCs
were injected i.v. into the tail vein without previous
ex vivo stimulation, using a different human donor in
each experiment.
Histology and Immunohistochemistry
From each mouse, spleen, lungs, liver, ileum and
colon, kidneys, skin, heart, and femur were isolated,
for a total of 20 morphological analyses per organ (2
experiments with 10 mice each). Each organ was split,
with one part frozen and stored in liquid nitrogen and
the other part fixed in PBS-buffered formaldehyde
(4%). The femur was decalcified with EDTA to enable
accurate bone marrow analysis. The formalin-fixed
organs were embedded in paraffin and tissue sections
were cut into 4-mm sections and mounted on coated
slides for staining with H & E for histology and with
various primary antibodies for immunohistochemistry
(Table 1).
Immunohistochemical staining was performed in
a Bond-Max automated immunostainer (Leica Micro-
systems,MiltonKeynes,UK).Slideswerepretreatedau-
tomatically with either citrate, using Bond Epitope
Retrieval Solution 1 (AR9961; Leica Microsystems), or
EDTA, using Bond Epitope Retrieval Solution 2
(AR9640; LeicaMicrosystems).Washing steps between
each reagent were performed using 1 BondWash So-
lution (LeicaMicrosystems).The stainingwas identified
by a polymer-based detection system with diaminoben-
zidine (DAB) using the Bond PolymerRefineDetection
Kit (DS9800; Leica Microsystems). This detection in-
cludes incubation with Post Primary for 15 minutes,
polymer for 8 minutes, and DAB for 10 minutes. The
sections were counterstained with hematoxylin.
For human FoxP3 staining, slides were deparaffi-
nized, washed, and blocked with endogenous peroxi-
dase blocker. Antigen retrieval was performed using
citrate pre-treatment, after which slides were washed
and incubated with diluted anti-human FoxP3uman Cells Injected in RAG22/2gc2/2 Mice
yclonal Clone Lot Dilution Pretreatment
AB75 127119 1:160 EDTA
4B12 247919 1:200 EDTA
C8/144B 51182 1:200 Citrate
L26 83 1:400 Citrate
JCB117 42791 1:200 Citrate
B-B4 605 1:1000 Citrate
- 44399 1:10000 Citrate
- 120 1:20000 Citrate
VS38C 38925 1:400 EDTA
KP1 211708 1:800 Citrate
PCH101 E021753 1:200 Citrate
FA-11 4817M21 1:50 None
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bated for 30 minutes with rabbit anti-rat HRP
(Dako, Glostrup, Denmark), diluted at 1:250, and
then incubated with Powervision goat anti-rabbit
IgG HRP (ImmunoLogic/Klinipath, Duiven, The
Netherlands), followed by staining with DAB for 10
minutes after washing with PBS. Slides were counter-
stained with hematoxylin.
Mouse CD68 staining was performed on frozen
tissue sections cut at 8 mm. Slides were fixed in acetone
for 10 minutes, then air-dried, rinsed in PBS, and
incubated with primary antibody for 1 hour. After rins-
ing, the slides were fixed in formaldehyde and blocked
with endogenous peroxidase blocker before being in-
cubated with a combination of horseradish peroxidase
(HRP)-conjugated rabbit anti-mouse antibody (Dako)
and 10% mouse serum (Dako) ar a dilution of 1:100.
Staining was identified using DAB and counterstained
with hematoxylin.
For all monoclonal and polyclonal antibodies used,
cross-reactivity against human antigens was tested using
both a positive control (human tonsil) and a double-
negativecontrol ineachrun.The latter consistedofacon-
trol staining using BALB/c tissue andmurine tissue from
RAG22/2gc2/2 mice without huPBMCs. In these
RAG22/2gc2/2 mice without huPBMCs, a control was
run with primary antibody and a control staining using
murine tissue with human cells without the primary anti-
body, to ruleout both false- positive stainingdue to cross-
reactivity of the other reagents used and false-negative
staining for the primary antibody. Cross-reactivity of
anti-murine CD68 was tested in human tonsil tissue.
Slides were assessed for the presence, severity, and
location of both fibrosis and cell infiltrates, including
the huPBMCs and murine macrophages, by 2 experi-
enced pathologists using light microscopy. The sever-
ity of infiltrate with respect to B cells, T helper cells,
cytotoxic T cells and plasma cells was scored on a scale
of 0 to 4, with 0 indicating no infiltration, 1 indicating
sporadic or\5% infiltration, 2 indicating mild infil-
tration of 5%-25%, 3 indicating moderate infiltration
of 25%-50%, or and 4 indicating severe infiltration of
.60%. Because the percentage of Tregs in human
blood varies from 1%-10%, different thresholds had
to be used to score the presence of human Tregs: 0,
no infiltration; 1, sporadic infiltration of approxi-
mately 1%; 2, mild infiltration of approximately 3%-
5%; 3, moderate infiltration of more than 5%-7%;
and 4, severe infiltration of more than 7%. Because
the percentage of infiltration was evaluated by light
microscopy, the scores are somewhat objective. A
Krippendorff’s k score of 0.6 was achieved when the
2 pathologists scored individually, but full agreement
was achieved by adding the possibility to score inter-
mediately between 2 consecutive scores when doubt
persisted and when scores were reevaluated by both
pathologists together.Cytokine Profile Analysis
The cytokine gene expression profile was analyzed
by qPCR tomeasure the amount of human andmurine
messenger RNA (mRNA) in themurine tissues. Tissue
samples were used from mice injected with huPBMCs
and from both RAG22/2gc2/2and Balb/c control
mice without huPBMCs. RNA was isolated from mu-
rine spleen, liver, lung, skin, colon and ileum using the
RNeasy Mini Kit (Qiagen, Venlo, The Netherlands),
according to the manufacturer’s instructions.
For each sample, 3 mg of RNA was incubated with
1 mL of both oligoDT (Promega, Leiden, TheNether-
lands) and Random Primers (Promega) for 5 minutes
at 70C.Then cDNAwas synthesized by adding amix-
ture of First Strand Buffer 5 (Invitrogen, Breda, The
Netherlands), 0.1 M DTT, and 10 mM dNTPs (Invi-
trogen), followed by incubation for 1 hour at 42C.
The cDNA was stored at 220C until use [27].
For all cytokines and other gene targets tested, hu-
man and mouse specificity was determined by testing
the primer–probe combination against mRNA isolated
from normal human and murine tissues (RAG22/2
gc2/2 and BALB/c mice). Only species-specific prede-
veloped TaqMan Assays were used (TaqMan Gene Ex-
pression Assay; Applied Biosystems, Foster City, CA).
The qPCR reactions were run on a LightCycler 480
real-time PCR system (Roche Diagnostics, Lewes,
UK). Each sample was run in duplicate, and a negative
control was used to exclude contamination. GAPDH
was used as a reference gene. Relative mRNA quantity
was measured using the E-method in the LightCycler
480 software (RocheDiagnostics). In thismethod, a cor-
rection for PCR efficiency is embedded in the
calculation of the relative quantity of gene expression.RESULTS
Clinical Symptoms
All mice injected with human cells (100%) showed
development of GVHD symptoms, including signifi-
cant weight loss, ruffled fur, reduced mobility, skin er-
ythema, and in some cases splenomegaly, as described
in other xenogeneic mouse models [15,23,28]. Human
chimerism levels in peripheral blood varied from
43%-100% (first experiment) to 5%-51% (second
experiment) at the time of death, with consistent
weight loss seen in all mice. The pattern of body
weight loss was similar to that described by van Rijn
et al. [15].
Histological Analysis
After injection of huPBMCs, many organs, includ-
ing spleen, lungs, liver, skin, bone marrow, gut, and
kidneys, were infiltrated with human cells. Because
mouse sacrifice was based on clinical criteria, mouse
survival varied, ranging from 29 to 70 days. The
1026 Biol Blood Marrow Transplant 18:1023-1035, 2012M. C. H. Hogenes et al.mice exhibited varying degrees of fibrosis in the vari-
ous organs; the longer the survival, the more severe
the fibrosis compared with the same organs in mice
with a shorter lifespan. Mice with higher human chi-
merism showed more prominent morphological
changes, as described below, although the patterns of
fibrosis and infiltrate migration in both experiments
were similar and showed clear changes compared
with control mice, either as a significant difference or
as a trend. Table 2 presents the number of fully exam-
ined mice per experiment, mean survival with standard
deviation, and mean scores per cell type per organ,
with standard deviation and P values. A complete de-
scription of individual scores of 4 organs in experiment
2 is provided in the Supplementary Data, Table S1.
Out of 20 mice, a total of 15 mice (6 from experiment
1 and 9 from experiment 2) could be fully examined.
Five mice died from the GVHD and were lost for eval-
uation because of severe postmortem lytic changes.
Spleen
The spleen contained large amounts of collage-
nous fibrosis around smaller blood vessels (Figure 1).
With longer survival time, the severity of the infiltrate
increased concurrently and the distribution of the
infiltrate became more diffuse. With more extended
infiltration through the tissue, the fibrosis spread in
the rest of the parenchyma as well, destroying the
entire morphology of the spleen.
Lungs and liver
Fibrosis around blood vessels was observed in the
lungs. The fibroses were concentrated around peri-
bronchial blood vessels and to a lesser degree around
bronchi and bronchioles whenmore extensive infiltrate
was present (Figure 2). The liver demonstrated peri-
portal fibrosis (Figure 3) lined with plasma cells along
the lamina limitans, with some bile duct proliferation.
Skin
Fibrosis was particularly extensive in the skin
(Figure 3). The morphology was quite similar to the
human sclerodermatous GVH reaction, with a mild
lichenoid infiltrate along the epidermal junction, thin-
ning of the epidermal layer, extension of coarse colla-
gen fibers in the dermis at the cost of the underlying
subcutaneous fat, and loss of hair follicles. Only
a few infiltrating human cells were present.
Bone marrow
The bone marrow showed clear signs of fibrosis,
but the cellularity of the marrow was maintained.
Other organs
There were no obvious signs of tissue damage in
the gut, in contrast to the human counterpart. Like-wise, the kidneys and heart demonstrated no signs of
tissue damage, despite the presence of human infiltrat-
ing cells (see below for specification).Morphological Infiltrate Analysis
Immunohistochemical staining revealed no cross-
reactivity between species, considering both primary
and secondary antibodies, and thus was considered
appropriate for determining the topographic location
of the different cells in the murine tissue.
As expected, no infiltrating human cells were found
in the control RAG22/2gc2/2mice. Only mouse mac-
rophages were observed in control mice tissues, using
anti-mouse CD68. In mice injected with human cells,
most of the human cell infiltrate was found in the
spleen, lungs, and liver, with little seen in skin, gut,
kidney, heart, and bone marrow. The different organs
showed typical consistent infiltration patterns, de-
scribed below. In general, most of the infiltrate con-
centrated in areas that would normally contain
lymphoid tissue in nonimmunodeficient mice and hu-
mans, and also around blood vessels. Human macro-
phages were not found in any organs, but mouse
macrophages (mouse CD681) were found mixed
with the human infiltrate, mainly in spleen, lungs,
and liver.
Spleen
In spleen, the infiltrating human cells first appeared
around blood vessels on day 29 andwith longer survival
spread diffusely in the parenchyma, with expansion of
the infiltrate (Figure 1). The infiltrate consisted of
a combination of huCD21 T cells (predominantly
CD81 cytotoxic T cells [CTLs]) with B cells
(huCD201 and huCD79a1) and a considerable num-
ber of plasma cells (huCD1381 and VS38c1). The B
cells and plasma cells were polyclonal for hu-l
and hu-k. The B cells and some plasma cells were usu-
ally found around blood vessels in a follicular pattern,
in the same areas that demonstrated fibrosis. This site
corresponds to the white pulpa zone in nonimmuno-
deficient species. T cells spread diffusely throughout
the parenchyma. Few Tregs (FoxP31) were detected
and those present were scattered throughout the tis-
sue. Murine macrophages (mouse CD681) were scat-
tered diffusely through the parenchyma (data not
shown).
Lungs and liver
In the murine lungs and liver (Figures 2 and 3), B
cells and plasma cells were concentrated around blood
vessels, with some spread along the bronchi. Mainly
larger arteries along the bronchi were surrounded by
a B cell infiltrate, closely matching the areas in which
fibrosis was detected histologically. T cells were
Table 2. Statistical Analysis of the Immunohistochemical Data
Fibrosis T Cells B Cells Plasma Cells Tregs
N
Survival, Days,
Mean (SD)
Histopathology Score,
Mean (SD) P Value
Histopathology Score,
Mean (SD) P Value
Histopathology Score,
Mean (SD) P Value
Histopathology Score,
Mean (SD) P Value
Histopathology Score,
Mean (SD) P Value
Spleen
Exp. 1 6 36.7 (7.2) 0.7 (0.8) .1028 3.2 (0.4) .0034 2.0 (0.9) .0052* 2.3 (1.5) .0049* 1.2 (0.4) .0034*
Exp. 2 9 39.5 (14.3) 1.8 (1.2) .0145* 3.7 (0.5) .0017 2.4 (1.0) .0047* 2.1 (1.2) .0061* 1.2 (1.3) .0615
Exp.1 vs. exp. 2 .0875 .0769 .2716 .9038 .9017
Liver
Exp. 1 6 36.7 (7.2) 1.5 (0.8) .0140* 2.7 (0.5) .0043* 1.2 (0.4) .0034* 1.5 (1.0) .0163* 0.3 (0.8) .4652
Exp. 2 9 39.5 (14.3) 1.7 (0.7) .0021* 2.0 (1.2) .0137* 0.8 (0.7) .0277* 0.6 (0.5) .0548 0.6 (0.5) .0545
Exp.1 vs. exp. 2 .9479 .3268 .2300 .0658 .3074
Lung
Exp. 1 6 36.7 (7.2) 0.5 (0.5) .0990 2.7 (0.5) .0043* 1.2 (0.4) .0034* 1.3 (0.5) .0043* 0.5 (0.8) .2230
Exp. 2 9 39.5 (14.3) 2.1 (1.0) .0024* 2.7 (0.5) .0017* 0.8 (0.8) .0603 0.7 (0.9) .1114 0.8 (0.4) .0090*
Exp.1 vs. exp. 2 .0069* .9429 .2993 .1171 .2880
Skin
Exp. 1 6 36.7 (7.2) 3.0 (0.9) .0052* 2.7 (1.0) .0050* 0.0 (0.0) † 1.0 (1.2) .01041 1.0 (1.2) .1041
Exp. 2 9 39.5 (14.3) 1.8 (0.8) .0023* 2.2 (1.0) .0024* 0.0 (0.0) † 0.0 (0.0) ‡ 0.4 (0.7) .1931
Exp.1 vs. exp. 2 .0322* .4587 † .1041 .4224
Colon
Exp. 1 6 36.7 (7.2) 0.7 (0.8) .1028 2.3 (0.5) .0043* 0.0 (0.0) † 0.0 (0.0) ‡ 0.2 (0.4) .4652
Exp. 2 9 39.5 (14.3) 2.4 (0.5) .00019 2.7 (1.2) .0060* 0.0 (0.0) .5500 0.0 (0.0) ‡ 0.1 (0.3) .5716
Exp.1 vs. exp. 2 .00030* .2800 .4960 ‡ .7768
Mean survival with standard deviation (SD), mean scores with SD and P values for histological and immunohistochemical scoring in the most important evaluated organs in experiment 1 (comparing mice injected with
huPBMCs and control mice without huPBMCs), experiment 2 (comparing mice injected with huPBMCs and control mice without huPBMCs) and comparing experiments 1 and 2 for differences between the groups of
mice with huPBMCs. An example of individual scoring in 4 organs from experiment 2 can be found in Table S1 in Supplementary Data.
*P value is significant.
†No B cells detected; t test not possible.
‡No plasma cells detected; t test not possible.
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Figure 1. Human infiltrating cells in spleen of RAG22/2gc2/2mice injected with huPBMCs. Infiltrate analysis of spleen comparing both histological and
immunohistochemical stainings of a control mouse and a mouse surviving 45 days after huPBMC injection is shown. The morphology is representative of
the observed reaction in a total of 15 examinedmice (6mice in experiment 1 and 9mice in experiment 2). (A) Normal murine spleen, without human cell
infiltrate or fibrosis (H & E staining; original magnification, 20). (B) Normal murine spleen without human cell infiltrate or fibrosis (AZAN staining;
original magnification, 20; fibrosis score 0). (C) Normal murine spleen, showing no immunohistochemical positivity and no cross-reactivity when stain-
ing for human CD21 T cells (huCD2 staining; original magnification, 20; T cell score 0). (D) Perivascular fibrosis in spleen in a mouse 45 days after
huPBMC injection (H & E staining; original magnification, 20; fibrosis score 2). (E) Perivascular fibrosis spleen (identical area to that shown in D) show-
ing blue staining of the formed collagenous fibrosis (AZAN staining; original magnification, 20; fibrosis score 2). (F) HuCD68 cells showing the absence
of human macrophages in a mouse injected with huPBMCs (huCD68 staining; original magnification, 20; macrophage score 0). (G) Follicular/perivas-
cular concentration of human B cells in the spleen after injection with human PBMCs (huCD20 staining; original magnification, 20; B cell score 2). (H)
Diffuse spreading of human T cells in the spleen after injection of human PBMCs (huCD2 staining; original magnification, 20; T cell score 4). (I) Focal
localization of human Tregs with nuclear positive staining for huFoxP3 after injection with human PBMCs (huFoxP3 staining; original magnification, 20;
Treg score 1). A circle indicates localization of capillary blood vessels; asterisk, fibrosis area; arrow, FoxP31 Tregs.
1028 Biol Blood Marrow Transplant 18:1023-1035, 2012M. C. H. Hogenes et al.distributed throughout the alveolar septae but were
also detected mixed with B cells perivascularly. Many
murine macrophages were found in the alveolar spaces
(Figure 2).
In the liver, the major sites of infiltration were the
periportal and pericentral area. B cells were located
around vessels, mainly the periportally and pericen-
trally located arteries (Figure 3). These areas closely
matched the areas of fibrosis in the previous histolog-
ical analysis. T cells were located in the hepatic sinuses,
along with an increased number of murine CD681
macrophages. There was a mixture of T helper cells
(CD41) and CTLs (CD81) in both lungs and liver,
with no predilection for either cell type. Only a few
Tregs were detected, not confined to specific areas in
the tissue.
Skin
The skin showed only small numbers of infiltrating
T cells (predominantly CD81 CTLs), located subepi-
dermally and surrounding hair follicles. Sporadically
a single Treg was detected, but no B cells or plasma
cells were identified (Figure 3). There was no correla-tion between the location of the previously described
fibrosis and the cellular infiltrate.
Gut
The gut (including colon and ileum) showed infil-
tration of T cells with scattered Tregs in the submu-
cosa, in areas where one would normally expect the
mucosal-associated lymphoid tissue in nonimmunode-
ficient species. In the colon, the infiltrate consisted
mainly of T helper cells (CD41). In the ileum there
was a relatively large amount of CTLs (CD81). As in
the skin, no B cells or plasma cells were observed.
Kidneys
The kidneys contained a mild infiltrate of T cells,
with a combination of CTLs (CD81) and T helper
cells (CD41), particularly around blood vessels and
sometimes near or in glomeruli.
Heart
In the heart, just a few T cells were detected within
major heart valves, but these could not be further spec-
ified. No human cells were found in the myocardium.
Figure 2. Histological and immunohistochemical analysis of infiltrating human cells in RAG22/2gc2/2 lungs. Infiltrate analysis of the lungs comparing
a control mouse and a mouse from experiment 1, surviving 45 days after huPBMC injection, is shown. The morphology is representative of the observed
pattern in a total of 15 examinedmice (6 mice in experiment 1 and 9 mice in experiment 2). (A) Normal murine lung showing thin alveolar septae around
bronchi and blood vessels (H & E staining; original magnification, 10; fibrosis score 0). (B) Lung after injection with human PBMCs, showing perivascular
and peribronchial fibrosis and cell infiltration with hypercellular alveolar septae 45 days after huPBMC injection (H & E staining; original magnification
10; fibrosis score 1). (C) Detail from (B) (inset) showing plasma cells in the area of fibrosis (H & E staining; original magnification 40; plasma cell score
1). (D) Normal lung showing thin alveolar septae without extensive fibrosis around bronchi or vessels (AZAN staining; original magnification, 10; fi-
brosis score 0). (E) and (F) Same areas as in (B) and (C) respectively, in AZAN staining, with blue staining of the collagenous fibrosis (E, original mag-
nification 10; (F) detail from (E) inset; original magnification, 40; fibrosis score 1). (G) Foamy alveolar macrophages after injection with huPBMCs (H &
E staining; original magnification, 40). (H) The macrophages do not show human CD68 positivity (huCD68; original magnification, 40; identical area
to that shown in H). (I) Positive staining of macrophages for mouse CD68 confirms murine origin (mouse CD68; original magnification, 40; identical
area to that shown in H). Br, bronchus. An asterisk denotes the peribronchial artery; an arrow, foamy alveolar bronchophages. The square is a detail of
the area shown in (C) (corresponding to the square in B) and (F) (corresponding to the square in D).
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The cellular bone marrow of the mice showed only
few scattered human cells, consisting mainly of T cells
(predominantly CD81) and sporadic plasma cells,
along with a few murine macrophages. No human B
cells and virtually no Tregs were present. The increase
in reticulin fibers could not be related to a specific
human cell type in these areas.Cytokine Profile
qPCR revealed high RNA levels for the human cy-
tokines transforming growth factor (TGF)-b and espe-
cially IFN-g in all organs tested. The calculated
relative quantities (RQ) for TGF-b were particularly
high in the liver compared with the spleen, lung,
skin, and gut (Figure 4). The data showed a mixture
of infiltrate in all affected organs, containing RNA
for cytotoxic T cells (CD8) and T helper cells
(CD4), including Th1 cells (Tbet) and Th2 cells
(GATA3), with some variation in the amounts of these
different cell types among organs. Th17 cells (RORC)
were also present, but Tregs (Foxp3) were found onlyin the spleen, lungs, and skin (Figure 5). The detected
variation in cell types based on qPCRmarkers was well
correlated with the previous immunohistochemical re-
sults. The expression of CXCR4 explained the attrac-
tion for lymphocytes to these organs. Furthermore,
only mouse-derived CD681 macrophages were de-
tected. Threshold cycle values for human CD68 were
very low, implicating a paucity of human macrophages
(Figure 4).
No fibrotic or other inflammatory-related cyto-
kines, such as FGF2, PDGF, or EGF (data not
shown), or BMP4 or CTGF mRNA of human origin
were detected (Figure 4). Expression of human RNA
for PAI was low in lung and very low in skin (data
not shown); however, high levels of murine CTGF
were found in the lung and skin (Figure 4). High levels
of murine TGF-b were observed as well, but this ap-
pears to be unrelated to human PBMC injection, given
that the level of murine TGF-b in control RAG22/2
gc2/2mice was as high or even higher. Murine
BMP4 was recovered at low levels from lung, skin, co-
lon, and ileum, and was detected in both test and con-
trol mice.
Figure 3. Histological and immunohistochemical analysis of infiltrating human cells in RAG22/2gc2/2 liver and skin. Infiltrate analysis comparing a con-
trol mouse with a representative mouse surviving 29 days (liver) and 45 days (skin) after huPBMC injection in experiment 1. The morphology is rep-
resentative of the observed fibrosis and cell infiltration patterns in a total of 15 examined mice (6 mice in experiment 1 and 9 mice in experiment
2). (A) Normal murine liver, showing no infiltrate or fibrosis in the portal tract (H & E staining; original magnification 20; control mouse, fibrosis score
0). (B) Liver after injectionwith human PBMCs, showing infiltration of human cells in the portal tract with extensive fibrosis and an intact bile duct 29 days
after huPBMC injection (H & E staining; original magnification 20; fibrosis score 2). (C) Area corresponding to that shown in (A) demonstrating green
staining of collagenous fibers in the hepatic portal area of normal mice (Trichrome staining; original magnification 20; fibrosis score 0). (D) Area cor-
responding to that shown in (B) showing extensive collagenous fibrosis (in green) in a mouse injected with huPBMCs (Trichrome staining; original mag-
nification 10; fibrosis score 2). (E) Normal murine skin, with many hair follicles in the dermis and normal presence of subcutaneous fat (H & E staining;
original magnification 20; control mouse, fibrosis score 0). (F) Skin 45 days after injection with huPBMCs, showing extensive fibrosis of the dermal
collagen at the cost of subcutaneous fat and infiltration of human cells subepidermally, perifollicularly, and interstitially (H & E staining; original magni-
fication 20; fibrosis score 4). (G) Area corresponding to that shown in (E) showing a normal ratio between dermal collagen (green) and subcutaneous
fat (Trichrome staining; original magnification, 20; fibrosis score 0). (H) Area corresponding to that shown in (F) showing extensive collagenous fibrosis
(green) in the dermis with a loss of subcutaneous fat (Trichrome staining; original magnification 20; fibrosis score 4). a, portal artery; v, portal vein;
asterisk, bile duct; s, subcutaneous fat; d, dermal tissue; e, epidermal layer; m, muscle.
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Figure 4. Expression of mRNA for fibrogenic proteins andmacrophagemarkers. Shown is the RQ of RNA for human andmurine TGF-b, CD68, BMP4,
and CTGF in spleen, lungs, liver, and skin of RAG22/2gc2/2 mice injected with huPBMCs.
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Here we report for the first time the exact, detailed
aspects of sclerotic GVHD in severe immunodeficient
RAG22/2gc2/2 mice injected with huPBMCs, with
a major focus on the morphology of the damaged
organs, infiltration patterns, and molecular aspects of
specific cytokines produced in the affected organs. In
humans, acute GVHD (aGVHD) is defined based on
temporal criteria as a reaction occurring within 100
days posttransplantation, and chronic GVHD
(cGVHD) is defined as a reaction developing 100
days or more posttransplantation. A small subset of pa-
tients with cGVHD develops a sclerodermatous
GVHD (ScGVHD) with fibrotic changes. The time-
based distinction between human aGVHD and
cGVHD cannot be translated to mouse models, how-
ever, because no murine model for GVHD has similar
kinetics as humans. Most mouse models demonstrateFigure 5. Expression of T cell marker mRNA. Shown is the RQ of RNA for dif
(Th1 cells), RORC (Th17 cells), CD4 (T helper cells), and CD8 (CTLs), includin
skin of RAG22/2gc2/2 mice injected with huPBMCs.lethal GVHD within 80 days posttransplantation.
This implies that GVHD studies in mice might be
better evaluated based on symptomatic similarities to
human aGVHD and cGVHD (eg, the ScGVHD
subtype), as opposed to time of onset. The distinction
between aGVHD and cGVHD in mice is based on
predominant T cell subset (Th1 in aGVHD and Th2
in cGVHD) and/or the presence of, for example, auto-
antibody production and systemic fibrosis [29]. Given
our qPCR results showing the presence of both Th1
and Th2 cells, we could not use this as a differentiation
criterion in our model. The presence of a systemic
fibrotic reaction suggests that in our model, a consis-
tent chronic reaction occurred that appears similar to
ScGVHD. Because the mice that we used were immu-
nodeficient, and thus the autoimmune component of
human chronic GVHD mediated by autoaggressive
T cells emerging from damaged thymus was not seenferent human cell types, including FoxP3 (Tregs), GATA3 (Th2 cells), Tbet
g CXCR4 (chemotactin for lymphocytes), in the spleen, lungs, liver, and
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antibodies. The sclerotic response in our model is me-
diated exclusively by mature peripherally derived
donor T cells.
Several humanizedmousemodels, includingNOG
[21], NOD/SCID [21], NOD/SCID IL2rgnull [29],
BALB/cA-RAG22/2IL2rg2/2 [21,29], and NOD/
SCIDb2mnull [23,29] as well as mouse-mouse models
(eg, D10.D2-injected BALB/c mice [30-32]), have
been used as models to study the diverse aspects of
GVH responses. Those previous studies reported
several histological features of a GVH reaction
with sclerotic changes, including lung fibrosis
[21,23,29,32], skin fibrosis [21,23,30], and fibrotic
changes in the liver [21,23,31]. Nevertheless, an exact
morphological description of these and other tissues
involved in our human-mouse model was lacking. Fur-
thermore, up to now, no specific infiltration patterns
for the different human cell phenotypes had been de-
scribed for xenogeneic mouse models or mouse-
mouse models.
In our model, human cells particularly infiltrated
the spleen, liver, and lungs. Only low quantities of hu-
man cells were detected in the skin, colon, ileum, and
kidney, and only sporadic cells were seen in heart
valves and bone marrow. This correlates with the
known sites of infiltration in previous xenogeneic
models [21,23]. The infiltrate showed a mixture of
CTLs and T helper cells (including Th1, Th2, and
Th17 cells), B cells, and plasma cells, based on
immunohistochemistry and qPCR data. The human
cells localized in areas that in nonimmunodeficient
species would contain lymphoid tissue (ie, spleen and
gut); however, in the lungs and liver, the expected
bronchial-associated lymphoid tissue was not in-
volved, and infiltrating B cells were often found around
blood vessels. The localization of B cells was confined
to spleen, lungs and liver. The T cells, including min-
ute amounts of Tregs, were spread diffusely through-
out the parenchyma or in the lymphoid origins. Only
murine macrophages (mouse CD681) were found in
spleen, liver, lung, skin, and gut, and no human
CD681macrophages were detected. The organs dem-
onstrated various degrees of fibrosis, with severity cor-
relating with survival time of the mice. Collagenous
fibers around blood vessels were detected in almost
all cases, and could proliferate and destroy the full ar-
chitecture of an organ in mice with longer lifespans,
correlating with the greater infiltration of human cells
in these mice.
As emphasized by Chu et al. [33] in a review of
mouse models for GVHD, mouse models might not
exactly match or mimic clinical GVHD, but they do il-
lustrate many aspects of the complex mechanism of
cGVHD, including ScGVHD, and thus are very use-
ful. Our data show that the morphology of the skin re-
action in our model is similar to that described in detailin other mouse-mouse models [30] and xenogeneic
models [21,23] and similar to the human skin
reaction seen in clinical ScGVHD. This includes the
paradox of low human cell infiltrate with nonetheless
evident fibrosis. Numerous previous studies have
attempted to relate this effect to either CD41 or
CD81 T cells. Although the GVHD effect in
immunodeficient mice is considered to be mediated
predominantly by CD41 cells [34,35], some studies
have reported the importance of CD81 cells in the
epidermis in both aGVHD and cGVHD skin biopsy
specimens [36] and oral cGVHD [37]. In our human-
ized mouse model, most T cells were CD81; however,
this does not explain the consequent low cell infiltra-
tion. Although T cell infiltration in the skin was low
compared with that in the spleen, lungs, and liver,
TGF-b and INF-g production in the skin was not sig-
nificantly different from that in the spleen and lung.
This finding supports the possibility of a direct role
of cytokines in inducing tissue damage, as suggested
by Dickinson et al. [38], independent of the quantita-
tive amount of human cell infiltrate.
In contrast to human GVHD and other xenoge-
neic models, the gut of the RAG22/2gc2/2 mice
showed no signs of damage, especially no signs of
apoptotic colitis, collagen deposition, or any other gas-
trointestinal features that would normally be expected
in human aGVHD and cGVHD. This finding might
be related to differences in intestinal bacterial micro-
flora in these specific pathogen-free–bred mice. The
intestinal flora is considered to play an important
role in fine-tuning the T cell repertoire in gut-
associated lymphoid tissue [39], although the exact
relationship with GVH response remains unclear.
The pathology in the lung is compatible to that
seen in other xenogeneic models and is to some extent
comparable to human ScGVHD, in which interstitial
fibrosis has been described as a bronchiolitis obliterans
pattern [40]; however, instead of being concentrated
along bronchioles, it was merely aligned with blood
vessels in our mice. In humans, cGVHD in the liver,
although rarely biopsied, shows either the classic signs
of bile duct epithelial injury with portal lymphocytic
infiltration or the hepatic variant with relatively mild
bile duct injury and lobular hepatitis [41]. Neverthe-
less, the loss of bile ducts in human cGVHDmight oc-
cur only late in the reaction [42,43], and clinical
cGVHD may mimic a variety of autoimmune and
immunodeficient diseases [33]. The liver morphology
in our model did show some resemblance to the histol-
ogy of human autoimmune hepatitis, including the
periportal fibrosis mentioned by Howell et al. [31].
Several cytokines are known to be involved in the
GVH reaction, including IFN-g and TGF-b [44].
Our qPCR data shows production of both human
and murine cytokines (Figures 4 and 5). The high
levels of TGF-b detected in our model are in line
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CTGF is a TGF-b–inducible early gene in
fibroblasts [48] that interacts directly with BMP4 and
TGF-b ligands in extracellular spaces. CTGF has
been found to correlate with the formation of sclerosis
in scleroderma [49,50], but has not been reported in
the context of ScGVHD [51]. In our model, high levels
of murine CTGF were detected, which could only
have been produced by nonlymphoid murine cells, be-
cause the lack of RAG2 and the gc-alleles prevented
the formation of murine B cells, T cells, and NK cells.
The significantly high levels of human TGF-b could
be produced only by human B cells and human T cells,
because human macrophages were lacking in our
model. Murine TGF-b and BMP4 were elevated in
both injected mice and control mice; thus, the high
level of TGF-b mRNA cannot be directly related to
the development of GVHD by huPBMCs. No expres-
sion of other fibrosis-related factors of murine or
human origin was detected. Given that IFN-g may
have various functions [52-55], the implications of
IFN-g in our process cannot be easily explained,
although it has been related to the fibrosis observed
in chronic allograft vasculopathy [56].
The interplay of donor cells and host-derived
antigen-presenting cells, to whichmacrophages belong,
and a monocyte-driven fibrotic reaction in the skin was
suggested previously [32,33]. Based on our results, we
conclude that there must be interplay among human B
cells and T cells and mouse macrophages at the level
of human TGF-b and INF-g with murine CTGF,
resulting in the formation of fibrosis.
Despite some differences with human cGVHD,
more specifically the human ScGVHD subtype, we
must agree with Chu et al. [33] and Schroeder et al.
[29] that mouse models are crucial for GVHD studies,
although the mouse model must be chosen wisely,
based on the targets of interest. Apart from differences
in GVH phenotype in various mouse strains (and even
in the same model for GVH response), the outcome of
the induced reaction often depends on conditioning
regimen, irradiation dose, donor source, and even
age of the mice undergoing transplantation [29]. In
our experiments, the level of human chimerism varied,
and some variation was observed when comparing the
scores of the histological or immunohistochemical
evaluation for significance. Nevertheless, we detected
a consistent pattern, either significant or at least as
a trend, for both morphology and migration in our
human-mouse model. Thus, we consider detailed his-
topathological features, including the similarities and
differences between mouse models and human
cGVHD (more specifically, ScGVHD), an absolute
necessity for future studies of GVHD.
In conclusion, our histological, immunohisto-
chemical, and molecular analyses of the ScGVHD in
the RAG22/2gc2/2 mouse have established thishuman-mouse model as relevant for the study of
ScGVHD and has enabled us to examined the various
processes involved in GVHD caused by either donor
or recipient cells. This opens the possibility of study-
ing specific therapeutic approaches directed at either
of these processes using reagents directed to either
mouse or human targets.ACKNOWLEDGMENTS
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